
    
      This is a Phase 1b, open-label, dose escalation, safety and tolerability study of Duvelisib
      (IPI-145) in combination with obinutuzumab in subjects with Chronic Lymphocytic
      Leukemia/Small Lymphocytic Lymphoma previously treated with a BTKi therapy.
    
  